Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil.
PMID: 34069929
2021
International journal of molecular sciences
Result: SDRM in PR were found in 5021 (24.82%) sequences and the more frequent were V82A (9.99%, n = 2021), M46I (9.58%, n = 1938), and I54V (8.50%, n = 1719).
Result: The SDRM with most similar prevalence when comparing both groups were M46I, V82A, L90M and I54V.
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.
Abstract: The DRMs most frequent were M184I/V (82.9%) for nucleoside reverse transcriptase inhibitors (NRTI), K103N/S (63.4%) for nonnucleoside reverse transcriptase inhibitor (NNRTI), and V82A/L/M (7.3%)
Result: Only half of the individuals had used PI (n = 46/82), only 17% of individuals presented DRMs associated with protease inhibitors (n = 14), and the most frequent mutations were V82A/L/M (6/82; 7.3%) and I54L/M/V (5/82; 6%), L90M (4/82; 4.8%), and M46L/I (4/82; 4.8%) (Figure 1).
Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
PMID: 34253143
2021
Journal of biomolecular structure & dynamics
Abstract: Here we showed that distinct changes in PR's active site, flap and elbow regions due to several PR resistance mutations (L10F, M46I, I54V, L76V, V82A) were found to alter LPV and DRV drug binding.
Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa.
PMID: 34278422
2021
The Journal of antimicrobial chemotherapy
Abstract: Major PI mutations, including M46I and V82A, were detected in 7.2% (9/125) of patients.
Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.
Result: Lopinavir was the only PI class that demonstrated significant HIVDRM with mutations at V32I (2 patients), I47 V/A (2 patients), and V82A/F/T/S (3 patients).
Correlation of HIV-1 drug resistant mutations and virologic failure.
PMID: 34584606
2021
The Pan African medical journal
Table: V82A
Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV.
PMID: 34289404
2021
International journal of antimicrobial agents
Abstract: The only patient (1.3%) with virological failure at Week 48 had poor adherence and baseline low-level resistance to darunavir with resistance-associated mutations at M46L, I50V and V82A.
HIV-1 molecular transmission network among sexually transmitted populations in Liaoning Province, China.
Result: Among them, 9 cases were protease inhibitor-related resistance, and the main resistance sites were L33F, V82A, Q58E, M46L, M46I; There were 4 cases of nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V75VI, K219Q, T215A, K65R; There were 5 cases of non-nucleoside reverse transcriptase inhibitor resistance, the main mutation sites were V179E, A98G, V106I, Y181C, G190S
Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.
Result: The combination mutation I54V+V82A confers intermediate resistance to all the currently approved PIs with the exception of darunavir, which retains full activity.
Result: We observed 4 PI-associated RAMs in 6 children/adolescents, as follows: the combination mutation I54V + V82A (n = 2), M46I/M (n = 1), and I84I/V (n = 1).
Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
HIV mutation literature information.
PMID: 
2021
International journal of molecular sciences
Browser Board
Co-occurred Entities
Filtrator
ViMRT